65,437 trials
Anxiety Disorder of Childhood · Separation Anxiety Disorder of Childhood · Social Anxiety Disorder of Childhood
Primary: Change From Baseline Anxiety Severity on the Pediatric Anxiety Rating Scale (PARS) at Week 12. — -11.82; -6.29; -8.47; -6.54 score on a scale
Type 2 Diabetes
Primary: Change From Baseline in HbA1c — -0.15; -1.26; -1.59; -1.45 percentage of HbA1c — p=<.001
Hypertension Pulmonary Secondary Heart Failure · Right Sided Heart Failure With Normal Ejection Fraction · Heart Failure With Normal Ejection Fraction
Primary: Clinical Safety — 33 Participants
Trauma · Trauma Injury · Hypoxemia
Primary: Occurrence of Hypoxemia — 5.1; 5.1 IR of episodes pr. 100 participant-hours — p=0.95
Breast Cancer
Primary: Percentage of Participants According to Number of Blood Tests at 1 to 4 Weeks From Palbociclib Treatment Initiation — 17.4; 12.9; 28.4; 29.7 Percentage of participants
Severe Combined Immunodeficiency
Primary: CD3 Cell Count Post Infusion — 5; 3 Participants
Prosthetic Joint Infection
Primary: Composite Endpoint of Overall Success at 90 Days — 33; 11 Participants — p=<0.0001
Oncolytic Virotherapy
Primary: Safety Parameters — 4; 3; 3; 3 Participants
Subchondral Cysts · Subchondral Bone Edema · Bone Marrow Edema
Primary: Overall Group Mean Improvement From Baseline of the Modified Harris Hip Score (mHHS) at 2 Years — 25.8; 26.3; 24.8 score on a scale
Alcohol Drinking · Marijuana
Primary: Alcohol Craving — 2.54; 2.64; 2.65; 2.55 units on a scale
Drug-drug Interaction Study
Primary: Maximum Observed Plasma Concentration (Cmax) of Pitavastatin — 42.79; 33.54 ng/mL
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8 · Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 · Clinical Stage I Esophageal Adenocarcinoma AJCC v8
Primary: Proportion of Participants With a Cardiac Event at 12 Months — 0.6818 proportion of participants
Obesity · Overweight and Obesity
Primary: Percent Change From Baseline in Body Weight at Week 32 — -0.85; -7.33; -15.6; -18.1 percent change
Migraine
Primary: Percentage of Participants With Pain Relief at 2 Hours Post-Dose: DBT Phase — 55.9; 32.7 Percentage of participants — p=<0.0001
Bronchopulmonary Dysplasia
Primary: Respiratory Adverse Outcomes — 27; 60 Participants